
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Congenital lesions originally thought to be a hemangioma often are something else. These experts in vascular abnormalities show you how to differentiate such tumors and malformations.






